Category: EDCs

Access Scientific Completes Study Demonstrating Superior Anti-Thrombotic Properties of POWERWAND Midlines and Extended Dwell Catheters

Access Scientific Completes Study Demonstrating Superior Anti-Thrombotic Properties of POWERWAND Midlines and Extended Dwell Catheters

May 23, 2018 – San Diego, Calif. — Access Scientific, LLC announced completion of an in vivo study demonstrating the superior anti-thrombotic (i.e., anti-clotting) property of its unique intravascular catheter material, ChronoFlex C® with BioGUARD™ technology.

The study found that ChronoFlex C with BioGUARD demonstrates thrombo-resistance where it matters most — on the surface of the blood vessel. No other catheter material has demonstrated this clinically important effect.

While other catheter manufacturers claim anti-thrombotic properties that reduce thrombus (clot) formation “on the surface of the catheter,” these anti-thrombotic claims cite in vivo or in vitro studies that show diminished thrombus formation solely on the surface of the catheter. This finding is often and mistakenly conflated with deep vein thrombosis (DVT) – a condition known to be associated with high-risk complications like bloodstream infection or blood clot embolization. There is no evidence that thrombo-resistance on the surface of the catheter has any effect on diminishing DVTs in actual patients.

Today’s announcement may serve to explain, at least in part, why Access Scientific’s POWERWAND™ catheters consistently demonstrate fewer DVTs and fewer total complications (including bloodstream infections) than other catheters used for similar purposes. “We now know it is not just the POWERWAND atraumatic insertion techniques that allow the vessel lining to remain clean and smooth,” said Steve Bierman MD, the company’s Chief Medical Officer. “It is also the catheter material, ChronoFlex C, and our patented BioGUARD processing, that makes POWERWAND anti-thrombotic both on the catheter surface and on the vessel wall.”

As hospitals continue to face the pressures of Value-Based Purchasing, novel products like POWERWAND offer solutions that both improve patient outcomes and reduce overall costs.

Access Scientific said that in the coming months it will reveal results of another completed study (pending publication). Combined with the current announcement of superior anti-thrombogenicity, this next study demonstrate the value of ChronoFlex C with BioGUARD as the ideal material for a wide variety of indwelling vascular catheters.

POWERWAND™ EDC – Success Stories

POWERWAND™ EDC – Success Stories

I guarantee you this news will make your professional life a whole lot easier and even more gratifying.

All over the world, vascular access specialists are now using ultrasound to help insert peripheral IVs (PIVs).  Because of this, central line insertions are often avoided and existing central lines are able to be discontinued. That’s the good news.

The bad news is: the median dwell time of ultrasound guided PIVs is 26 hours, and their failure rate is nearly 50%. Ultrasound-guided PIVs just cannot last, they are too short and made of the wrong material (i.e. polyurethane).

Fortunately, Access Scientific has the solution—POWERWAND™ EDC: The first power-injectable, non-trimmable 6cm extended-dwell, 3Fr catheter, specifically designed for ultrasound-guided peripheral IV access.  Like all POWERWANDs, the EDC is made of ChronoFlex™C and inserted using either the XL method (easiest) or the accelerated Seldinger technique (fastest).

Does it perform?  Preliminary data from a prestigious urban hospital—currently in the process of publishing these remarkable results—revealed the POWERWAND™ EDC average dwell time of 11.2 days.  That’s longer than the vast majority of midlines! And, the POWERWAND™ EDC resulted in a 39.1% reduction of central line usage. No other peripheral IV in the world can boast such extraordinary results.

Imagine not having to go back again and again to the same patient to start and restart an ultrasound-guided PIV.  Imagine not having to ultimately start a PICC or CVC and risk a CLABSI on that poor patient. Imagine the patient and family sincerely offering you their thanks.

There is a new and better tool in your toolbox—the revolutionary 6cm, 3Fr POWERWAND™ EDC.  I’m sure if you try it, you’ll quickly realize it is by far the best peripheral vascular access device ever made.

Patients First.

Steve Bierman MD

New Study Proves POWERWAND Safe for Vancomycin Delivery

New Study Proves POWERWAND Safe for Vancomycin Delivery

Definitive proof has finally arrived.  PICCs are no longer required to deliver long-term or short-term vancomycin (4mg/ml). Over 1000 patients, representing over 8000 catheter-days, are reported in this month’s JAVA to have had no DVTs and no bloodstream infections and minimal phlebitis (0.6%) during intravenous vancomycin administration through the POWERWAND midline. (Full article)

What does this groundbreaking study mean for you and your institution?

In most hospitals, vancomycin administration is an indication for about 20% of PICCs.  This new POWERWAND study demonstrates that these patients no longer need PICCs, which means you can reduce your central line days by roughly 20%. Instead of a PICC, a 4Fr or 5Fr POWERWAND placed in the deep vessels of the upper arm will get the job done safer and more cost-efficiently. In fact, placing a POWERWAND is usually at least $90.00 less expensive than placing a PICC.

Remember, only the POWERWAND midline has over 20,000 catheter days of published data attesting to zero bloodstream infections and the lowest complication rates of any vascular access device ever studied. (refs) Couple this with the news of safe vancomycin administration (over 5 years, in over 1000 patients) and you really have compelling reasons to support your POWERWAND use.

It’s a pleasure to share this information with you, because it means that everyone—patients and providers—gets to share the benefits POWERWAND use.  Thank you for your continued, evidence-based support.

Steve Bierman, MD

Chief Medical Officer


POWERWAND Midline Program Guaranteed to Protect Against Costly CMS Penalties

POWERWAND Midline Program Guaranteed to Protect Against Costly CMS Penalties

Central Line-Associated Bloodstream Infections (CLABSIs), which are “Never Events,” cost hospitals significantly more than the reported $56,000 per incident.1 Because of CMS’ current reimbursement policy, CLABSIs can ultimately cost hospitals several millions of dollars.
One simple measure–the adoption of a robust midline program–can reduce central line days (CLDs) and CLABSIs, saving hospitals enormous expense. However, not all midlines can yield such important, cost-saving results. In order to affect real change and reduce central lines, facilities need to implement an evidence-based midline policy founded on published data showing low complications (especially, low infection rates) and high completion of therapy. When implementing a midline program, it is important to partner with a company that is truly interested in helping your facility reduce central lines days and CLABSIs, and that is also willing to engage in risk sharing agreements that guarantees your facility will meet targeted goals.
There is only one midline catheter proven to reduce both central line days and CLABSIs. A ground-breaking 2015 study in Infectious Disease and Clinical Practice proved the use of the POWERWAND midline decreased the total number of central line days in a ventilator ICU by 37% and reduced CLABSIs by 100% over a 12-month study period.2 These results were driven by the POWERWAND’s unparalleled performance, highlighted by its high flow rate, blood drawability, and kink resistance. With the POWERWAND, physicians recognized they had dependable access, meaning they did not need to leave high-risk central lines in place as a safeguard.  Again, this reduced CLABSIs to zero.
Not all midlines are equal, as illustrated by the data in figure 1. After using a competitive midline for ten months, across five ICUs in a large teaching hospital, the facility was still utilizing 787 CLDs per month, resulting in 15 CLABSIs over the 10-month period and a CLD utilization ratio (UR) of 0.45.  After switching to the POWERWAND, they reduced their CLDs by 30%, CLABSIs were reduced by 27% – resulting in a savings of $224,0001 — and their CLDUR dropped by 28%. Generating and sustaining these results through the use of the POWERWAND may qualify the hospital for full reimbursement and potential bonuses. The competitive midline, again, offered no such benefit. There were no bloodstream infections associated with POWERWAND midline during the data collection period. POWERWAND has over 20,000 catheters days of published scientific data without a single catheter-related bloodstream infection (CRBSI).
Figure 1 - DataFigure 1 – Data collected over two 10-month periods confirms POWERWAND offers significantly superior clinical outcomes and cost savings benefits.
Patient safety plays a major role in Value-Based Purchasing. As a result, healthcare facilities need to demonstrate they have taken all necessary steps to increase the safety of their patients. The POWERWAND Midline Program provides the hospital with a proven process that educates the staff and instills best practices throughout the facility. This process helps reduce patient risk through the elimination of unnecessary central lines. The POWERWAND provides the healthcare facility a true alternative to central lines, thereby eliminating the associated CVC risks, as well as repetitive needlesticks required by standard peripheral IV catheters (PIVs).  Patient satisfaction and safety scores rise when POWERWAND midlines are introduced.
Again, implementation of the POWERWAND’s robust midline program translates into improved reporting data:
  • The insertion of unnecessary, high-risk central lines is eliminated
  • Removal of central lines occurs sooner — when central access is no longer indicated
  • Fewer infections
    • Ultimately, this lowers SIR, which is measured by CMS
POWERWAND Central Line Day Reduction Guarantee and Cost Savings
POWERWAND has more clinical support data than any other catheter on the market. Because of the low total complications and high completion of therapy, POWERWAND allows hospitals to implement a midline program that will reduce central line days, increase staff adherence to midline policies and procedures, and increase patient satisfaction – guaranteed.
Benefits of implementing the POWERWAND Midline Program and CLD Reduction Guarantee:
  • Hard cost savings can be as great as $1003 per procedure compared to central lines
  • Up to $56,0001 in clinical savings by the reduction of just one CLABSI
  • Guaranteed reduction in central line days (risk sharing)
  • Improved standardized infection ratio (SIR)
  • Improved reimbursement through CMS Value Based Purchasing
  • Improved patient satisfaction scores
1. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 2013;173:2039-46.
2. Pathak R, Patel A, Enuh H et al. The Incidence of Central Line–Associated Bacteremia After the Introduction of Midline Catheters in a Ventilator Unit Population. Infect Dis Clin Prac 2015;23(3): 131-134.
3. Caparas JV, Hu JP. Safe administration of vancomycin through a novel midline catheter: a randomized, prospective clinical trial. J Vasc Access. 2014;15(4):251-256.
Full Text: POWERWAND Midline Program Guaranteed to Protect Against Costly CMS Penalties